Reagent Production/Sales

Benchmark produces custom hyperimmune anti-serum, made to meet client needs including specific QC or assay requirements.  To avoid delays in arrival, please make sure all import permits are in place to receive diagnostic material.  See links below for more information.

  1. BenchReady Serum Products
    • Satisfactory for the following 9CFR testing:
      • Sterility (9CFR 113.26)
      • Mycoplasma (9CFR 113.28)
      • Hemadsorbing and cytopathogenic agents (9CFR 113.46)
      • Extraneous viral agents (9CFR 113.47)
    • Provide Alpha-neutralization indexes to
      • the homologous virus,
      • if applicable, other serotypes of the virus,
      • to additional agents that may be used in similar assays to show cross-reactivity
    • Additional testing can be requested
  2. BenchReady Cell Stocks
    • Satisfactory for the following 9CFR testing:
      • Sterility (9CFR 113.26)
      • Mycoplasma (9CFR 113.28)
      • Hemadsorbing and cytopathogenic agents (9CFR 113.46)
      • Extraneous viral agents (9CFR 113.47)
    • Additional testing can be requested

Reagents currently available have been 9CFR tested and may be purchased in 1ml vials or bulk. Serum available include the following:

Mono-Specific Hyperimmune Polyclonal Sera:

  • Porcine anti-BVD
  • Porcine anti-PI3
  • Porcine anti-BHV-1
  • Porcine anti-CAV-2
  • Porcine anti-CDV
  • Porcine anti-CPI
  • Porcine anti-CPV
  • Porcine anti-CCV
  • Porcine anti-BRSV
  • Porcine anti-FCV
  • Porcine anti-FRV

Primary Cells (Tested according to 9CFR):

  • Bovine turbinate
  • Dog kidney
  • Embryonic bovine kidney
  • Embryonic bovine lung
  • Feline kidney
  • Swine kidney
  • Equine dermal

Please contact us for current availability and pricing.

 

For more information regarding import permits:

http://www.aphis.usda.gov/animal_health/vet_biologics/vb_import_export_products.shtml

http://www.aphis.usda.gov/animal_health/permits/downloads/vs16-3-inst_can.pdf

http://www.aphis.usda.gov/animal_health/vet_biologics/publications/memo_800_101.pdf